AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AIM ImmunoTech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.16−0.01 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
AIM ImmunoTech Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Treatment Programs - US [Member] | $30.00K | $33.00K | $50.00K | $33.00K | $23.00K | $28.00K | $34.00K | $27.00K | – | – | 100.0% | +30.4% |
| Clinical Treatment Programs - Europe [Member] | – | – | – | – | – | – | $8.00K | $9.00K | – | – | – | – |
By region
| Revenue | Q2 22 | Q1 22 | Q4 21 | Q3 21 | Q2 21 | Q1 21 | Q4 20 | Q3 20 | Q2 20 | Q1 20 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Europe [Member] | – | – | – | – | – | – | – | – | $0 | $2.00K | – | – |
| US [Member] | – | – | – | – | $23.00K | $28.00K | – | – | $40.00K | $43.00K | – | – |
From the segment and revenue-disaggregation notes of AIM ImmunoTech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.